Early-stage cost-utility analysis of novel diagnostic tests for giant cell arteritis: a modelling study in UK secondary care
The study highlights the potential for hypothetical tests to improve GCA diagnosis and reduce glucocorticoid toxicity, while demonstrating their market viability for use within the NHS. It also illustrates how early-stage economic models can provide valuable insights into potential cost-effectiveness to inform the test development process.
Authors
- Ann W Morgan (ORCID: https://orcid.org/0000-0003-1109-624X)
- Miaoqing Yang (ORCID: https://orcid.org/0000-0001-7975-374X)
- Paola Cocco (ORCID: https://orcid.org/0000-0002-0652-6877)
- Sarah Mackie (ORCID: https://orcid.org/0000-0003-2483-5873)
Institutions
- University of Leeds (GB)
- Leeds Teaching Hospitals NHS Trust (GB)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1136/bmjopen-2025-102888
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- AstraZeneca
- Sanofi
- National Institute for Health and Care Excellence
- National Institute for Health and Care Research
- British Heart Foundation
- Department of Health and Social Care
- Versus Arthritis
- Chugai Pharmaceutical
- Medical Research Council
- Leeds Biomedical Research Centre